Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Respiratory, thoracic and mediastinal disorders – page 51

  • 1 276 clinical trials
  • 446 recruiting
  • 379 conditions
  • 28 countries

Conditions in this area

379 conditions with trials, the busiest first

Non-small cell lung cancer327Asthma88Non-small cell lung cancer metastatic82Chronic obstructive pulmonary disease60Non-small cell lung cancer stage IV57COVID-1939Pulmonary arterial hypertension38Non-small cell lung cancer stage III37Idiopathic pulmonary fibrosis34Pneumonia32Small cell lung cancer32Non-small cell lung cancer stage IIIB31Small cell lung cancer extensive stage31Influenza28Interstitial lung disease28Lung neoplasm malignant28Cystic fibrosis24Conjunctivitis allergic23Pulmonary hypertension23Chronic rhinosinusitis with nasal polyps21Respiratory syncytial virus infection20Rhinitis allergic20Post-acute COVID-19 syndrome19Ovarian cancer18+355

Clinical trials in Respiratory, thoracic and mediastinal disorders

1 276 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 276 clinical trials

Endometrial cancer+3

Not yet recruiting

Study of Disitamab Vedotin for Adults with Previously Treated HER2-Positive Solid Tumors, Including Lung, Head and Neck, Ovarian, and Endometrial Cancers

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Disitamab Vedotin
  • Sponsor:Seagen Inc.

Bronchiectasis

Not yet recruiting

Study on Inhaled Tobramycin and Colistimethate Sodium for Adults with Chronic Bronchial Infection in Bronchiectasis

Registered drug
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Tobramycin
  • Sponsor:Consorci Mar Parc De Salut De Barcelona

Non-small cell lung cancer+1

Not yet recruiting

Study of SYM024, SYM023, and SYM025 in Adults with Advanced Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Expression

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Institut De Recherches Internationales Servier IRIS

Small cell lung cancer

Not yet recruiting

Study on the Safety and Effectiveness of AL8326 for Patients with Small Cell Lung Cancer Needing Second-Line Treatment

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Al8326
  • Sponsor:Advenchen Pharmaceuticals LLC

Idiopathic pulmonary fibrosis

Not yet recruiting

Study on Inhaled Phospholipid Fraction from Bovine Lung for Patients with Idiopathic Pulmonary Fibrosis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Phospholipid Fraction, Bovine Lung
  • Sponsor:Philipps-Universitaet Marburg

Asthma

Not yet recruiting

Study on the Effects of Dexpramipexole for Adolescents and Adults with Severe Eosinophilic Asthma

Registered drug
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Budesonide
  • Sponsor:Areteia Therapeutics Inc.

Respiratory syncytial virus infection

Not yet recruiting

Study on the Safety and Tolerability of Sisunatovir in Infants and Children with RSV Infection

Investigational
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Sisunatovir
  • Sponsor:Pfizer Inc.

Upper respiratory tract infection

Not yet recruiting

Study on the Effectiveness and Safety of Ibuprofen and N-Acetylcysteine for Patients with Upper Respiratory Tract Infections with Wet Cough

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Acetylcysteine
  • Sponsor:E Pharma Trento S.p.A.

Non-small cell lung cancer metastatic

Not yet recruiting

Study Comparing ONC-392 and Docetaxel for Patients with Metastatic Non-Small Cell Lung Cancer After PD-1/PD-L1 Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Oncoc4 Inc.

Non-small cell lung cancer metastatic

Not yet recruiting

Study Comparing Ivonescimab and Chemotherapy with Pembrolizumab and Chemotherapy for Patients with Metastatic Squamous Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Summit Therapeutics Inc.

Pulmonary sarcoidosis

Not yet recruiting

Study on the Effects of OATD-01 for Patients with Active Pulmonary Sarcoidosis

Investigational
Countries:DenmarkDenmark
  • Participants:18–64 years
  • Substances:5-(4-((2S,5S)-5-(4-Chlorobenzyl)-2-Methylmorpholino)Piperidin-1-Yl)-1H- 1,2,4-Triazol-3-Amine
  • Sponsor:Molecure S.A.

Chronic obstructive pulmonary disease

Not yet recruiting

Study on Oxygen Therapy and Salbutamol for Patients with COPD Exacerbation

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Air, Medicinal
  • Sponsor:Præhospitalet

Substances studied in this area

The therapies tested most often in Respiratory, thoracic and mediastinal disorders trials.

Carboplatin169 clinical trialsPembrolizumab145 clinical trialsCisplatin128 clinical trialsPemetrexed108 clinical trialsPaclitaxel80 clinical trialsDurvalumab71 clinical trialsAtezolizumab50 clinical trialsNivolumab49 clinical trialsSodium Chloride49 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.